フェネック・ファーマシューティカルズ
Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | 0.01 | $15M | $2M |
| 2025 Q4 | -0.17 | $14M | -$6M |
| 2025 Q3 | -0.02 | $12M | $1M |
| 2025 Q2 | -0.12 | $10M | -$4M |
| 2025 Q1 | -0.04 | $9M | -$4M |
| 2024 Q4 | -0.07 | $8M | -$1M |
| 2024 Q3 |
| -0.21 |
| $7M |
| -$2M |
| 2024 Q2 | -0.20 | $7M | -$8M |